IBA57 Deficiency (Multiple Mitochondrial Dysfunctions Syndrome Type 3) – Overview
IBA57 deficiency is a rare autosomal recessive mitochondrial disorder caused by pathogenic variants in the IBA57 gene, leading to a neurometabolic disease most commonly classified as multiple mitochondrial dysfunctions syndrome type 3 (MMDS3). Major rare-disease resources, including Orphanet, NORD, OMIM, and MedGen, list “IBA57 deficiency” as a synonym for MMDS3. The disorder is characterized by an infantile- or early childhood–onset mitochondrial leukoencephalopathy with variable severity, ranging from rapidly fatal neonatal disease to more slowly progressive forms with partial stabilization.[1][2][3][4][5]
Biallelic IBA57 variants can also cause a spectrum that includes hereditary spastic paraplegia type 74 (SPG74) and a SPOAN-like phenotype, showing that IBA57-related disease is broader than classic MMDS3. Nonetheless, MMDS3 remains the best defined clinical entity and is usually what is meant by “IBA57 deficiency” in clinical practice.[6][7][8][3]
Genetic and molecular basis
The IBA57 gene and protein
IBA57 (iron–sulfur cluster assembly factor IBA57) encodes a mitochondrial protein involved in the late steps of iron–sulfur (Fe–S) cluster assembly for a subset of mitochondrial [4Fe–4S] proteins. Orphanet and gene‑centric databases describe IBA57 as an iron–sulfur cluster assembly factor required for the maturation of specific Fe–S proteins, including components of the respiratory chain and metabolic enzymes. IBA57 is highly conserved and localizes to the mitochondrial matrix, where it interacts functionally with other Fe–S assembly proteins such as NFU1 and ISCA1/2.[9][8][10][3][11]
Role in mitochondrial metabolism
Experimental studies in human cells and model systems show that IBA57 is critical for the maturation of [4Fe–4S] clusters in respiratory chain complexes I and II, mitochondrial aconitase, and lipoic acid synthase (LIAS). Deficiency of IBA57 leads to reduced activity and/or abundance of complex I and II subunits, impaired aconitase function, and decreased LIAS levels, which in turn causes defective lipoylation of key mitochondrial enzymes such as pyruvate dehydrogenase and α‑ketoglutarate dehydrogenase. This combined defect in respiratory chain function and lipoic‑acid–dependent dehydrogenases underlies the severe impairment of oxidative metabolism seen in MMDS3.[2][8][10][3][6]
Recent mechanistic work indicates that IBA57 deficiency can secondarily reduce expression of NFU1, another Fe–S assembly factor, further compromising SDH (complex II) activity and lipoic acid synthesis. Cellular complementation experiments with mutant IBA57 alleles show incomplete rescue of Fe–S–dependent enzyme activities, directly supporting the pathogenicity of specific variants.[7][10][6]
Epidemiology
Orphanet estimates the prevalence of MMDS3/IBA57 deficiency at <1 in 1,000,000 individuals, consistent with an ultra‑rare disease. Fewer than 100 affected individuals have been reported worldwide in aggregated case series and literature reviews. The disorder follows an autosomal recessive inheritance pattern; most affected children are born to carrier parents who are clinically unaffected, and many reported families have consanguinity.[8][3][1][7]
Pathophysiology
IBA57 deficiency disrupts the mitochondrial iron–sulfur cluster (ISC) assembly system, specifically affecting maturation of a subset of [4Fe–4S] proteins. As a result, there is a combined deficiency of respiratory chain complexes I and II, impaired mitochondrial aconitase, and reduced activity of lipoic‑acid–dependent dehydrogenase complexes, leading to profound mitochondrial dysfunction. Biochemically, this manifests as decreased activities of complexes I and II in muscle or fibroblasts, elevated blood and CSF lactate, and secondary abnormalities in organic acids and amino acids (e.g., increased CSF glycine).[10][3][12][2][8]
These mitochondrial defects predominantly affect white matter tracts in the brain, resulting in a characteristic mitochondrial leukoencephalopathy with cavitating lesions in periventricular and parieto‑occipital regions. Energy failure in motor pathways and optic pathways contributes to hypotonia, spasticity, and vision loss, while global neuronal vulnerability explains encephalopathy and seizures.[3][1][10]
Clinical spectrum and natural history
Age of onset and course
Orphanet and NORD describe IBA57 deficiency as typically presenting in the neonatal period or early infancy, although later childhood onset with milder progression has been reported. Many infants have an initial period of apparently normal development followed by acute or subacute regression of motor and cognitive milestones, often triggered by intercurrent illness. The clinical course is highly variable: some children experience rapid deterioration leading to early death from respiratory failure, while others have more protracted disease with partial recovery or stabilization after initial worsening.[4][1][2][3]
Neurological manifestations
Common neurological features include hypotonia, weakness, and encephalopathy with progressive loss of previously acquired motor skills and developmental delay. Spasticity, pyramidal signs, and spastic paraplegia develop in many patients, reflecting involvement of corticospinal tracts; in some families, a chronic spastic paraplegia phenotype (SPG74‑like) dominates. Seizures, including focal and generalized types, are frequently reported and may be difficult to control in severe cases.[1][7][2][8][3]
Visual impairment is another key feature: affected individuals may develop optic atrophy and progressive vision loss. Feeding difficulties, bulbar dysfunction, and respiratory muscle weakness contribute to aspiration risk and respiratory failure, a major cause of morbidity and mortality.[7][2][3][4][1]
Systemic and growth features
As with other MMDS, infants and children with IBA57 deficiency may show failure to thrive, poor weight gain, and feeding intolerance. Intercurrent infections can precipitate metabolic decompensation with worsening lactic acidosis, encephalopathy, and neurologic regression. Some reports note episodic deterioration followed by partial improvement, suggesting that, beyond an underlying progressive component, there is also vulnerability to metabolic stress.[12][2][8][3]
Neuroimaging
Brain MRI in IBA57 deficiency typically shows a mitochondrial leukoencephalopathy with cavitating or cystic lesions. Lesions predominantly involve the periventricular and deep cerebral white matter, especially in the parieto‑occipital regions, and may progress from diffuse signal changes to frank cavitation. Some patients also demonstrate involvement of brainstem tracts, cerebellar white matter, or corpus callosum; serial imaging demonstrates evolution of cavities over time.[10][3][1]
These imaging findings can overlap with other causes of cavitating leukoencephalopathy, but the combination of the MRI pattern, biochemical profile, and biallelic IBA57 variants is characteristic for MMDS3.[3][10]
Biochemical profile
Reported biochemical abnormalities include elevated serum and CSF lactate, consistent with impaired oxidative phosphorylation. Several patients have elevated CSF glycine and evidence of combined deficiency of mitochondrial respiratory chain complexes I and II on muscle or fibroblast enzymology. Additional evidence of defective lipoic acid metabolism includes decreased activity of 2‑oxoacid dehydrogenases such as pyruvate dehydrogenase and α‑ketoglutarate dehydrogenase.[5][2][10][3]
Metabolomic studies have suggested characteristic alterations in lysine and tryptophan metabolites that may serve as potential biomarkers for MMDS3, although these remain investigational.[12]
Diagnosis
Clinical suspicion
IBA57 deficiency should be suspected in infants or young children with:
- Early‑onset neuroregression or developmental delay.
- Hypotonia evolving to spasticity, often with optic atrophy and seizures.
- MRI evidence of cavitating or cystic leukoencephalopathy, especially in periventricular and parieto‑occipital white matter.
- Biochemical evidence of mitochondrial dysfunction (lactic acidosis, combined complex I/II deficiency).[2][1][3]
A family history of similarly affected siblings or parental consanguinity can further raise suspicion of an autosomal recessive mitochondrial disorder such as MMDS3.[8][3]
Laboratory and neuroimaging investigations
Initial work‑up typically includes serum and CSF lactate, amino acids, acylcarnitines, and urine organic acids to screen for mitochondrial and other inborn errors of metabolism. Elevated lactate (± CSF glycine), plus supportive changes on neuroimaging, should prompt more detailed mitochondrial evaluation. Muscle biopsy or fibroblast studies may demonstrate combined deficiency of respiratory chain complexes I and II, while complexes III and IV may be relatively preserved, reflecting selective vulnerability of [4Fe–4S]–dependent enzymes.[5][2][8][10][3]
MRI with and without contrast is essential to define the pattern of white matter involvement and cavitation; MR spectroscopy may show lactate peaks in affected regions. When available, advanced imaging and serial follow‑up can help distinguish MMDS3 from other leukodystrophies with cystic changes.[10][3]
Genetic testing
Definitive diagnosis rests on identifying biallelic pathogenic or likely pathogenic variants in IBA57 via:
- Targeted sequencing of the IBA57 gene when clinical suspicion for MMDS3 is high.
- Broader gene panels for mitochondrial disease or leukodystrophy.
- Whole‑exome or whole‑genome sequencing when the diagnosis is uncertain.[13][1][8]
MedGen, OMIM, and ClinVar catalog multiple pathogenic IBA57 variants (missense, frameshift, and splice) associated with MMDS3, often affecting conserved residues in the protein. Functional studies in selected cases show reduced IBA57 protein expression, decreased activities of complexes I and II, and partial rescue upon expression of wild‑type IBA57, supporting the causative role of these variants.[14][6][7][5][10]
Differential diagnosis
The main differential diagnoses include other multiple mitochondrial dysfunctions syndromes (MMDS1–2,4–6) due to NFU1, BOLA3, ISCA2, ISCA1, and PMPCB variants, which share overlapping clinical and biochemical features. These conditions often present with early encephalopathy, lactic acidosis, respiratory failure, and combined respiratory chain deficiencies, but may have distinct MRI patterns or involvement of pulmonary hypertension and cardiomyopathy in some subtypes (e.g., NFU1, BOLA3).[8][3]
Other considerations are mitochondrial leukodystrophies and cavitating leukoencephalopathies of different etiologies, such as POLG‑related disease, LIPT1 or LIAS‑related lipoic acid synthesis defects, and non‑mitochondrial leukodystrophies with cystic changes. The specific MRI pattern, targeted biochemical work‑up, and molecular findings help distinguish these entities.[11][8][10]
Management
General principles
There is no curative or disease‑modifying therapy currently established for IBA57 deficiency; management is largely supportive and symptomatic, consistent with general approaches to mitochondrial and leukodystrophy disorders. Care is best provided by a multidisciplinary team including neurology, metabolic/genetics, nutrition, physiatry, and palliative care specialists.[1][3][8]
Acute management
During acute decompensation (e.g., triggered by infection), priorities include:
- Stabilization of airway, breathing, and circulation, with early respiratory support if needed.
- Aggressive treatment of infections and avoidance of prolonged fasting to reduce catabolic stress.
- Management of seizures with appropriate antiseizure medications, avoiding drugs with known mitochondrial toxicity where possible.[3][8]
Intravenous fluids with adequate glucose may help prevent catabolism, although specific protocols for MMDS3 have not been standardized and are extrapolated from broader mitochondrial disease practice.[8]
Chronic and supportive care
Long‑term management focuses on optimizing quality of life and minimizing complications:
- Seizure control with antiepileptic drugs tailored to the individual; some patients respond reasonably, while others have refractory epilepsy.[2][1][3]
- Nutritional support, including consideration of gastrostomy tube placement in children with severe dysphagia or aspiration risk.[1][2]
- Physical, occupational, and speech therapy to maintain function, prevent contractures, and support communication.[3][8]
- Vision services and low‑vision rehabilitation when optic atrophy and visual loss occur.[7][3]
- Proactive respiratory care, including airway clearance techniques, non‑invasive ventilation, and monitoring for nocturnal hypoventilation in advanced disease.[2][1]
Mitochondrial supplements and experimental approaches
Some clinicians empirically use mitochondrial “cocktails” (e.g., coenzyme Q10, riboflavin, l‑carnitine, lipoic acid), but there is no robust evidence that these agents alter the course of IBA57 deficiency. Case reports and small series occasionally describe partial clinical improvements or stabilization, but controlled studies are lacking. Given the central role of Fe–S cluster assembly and lipoic acid synthesis, future targeted therapies may focus on modulating these pathways, but such strategies remain experimental.[6][12][10][8][3]
Prognosis
Prognosis is highly variable, with some infants experiencing rapidly progressive encephalopathy and early death, while others survive into later childhood with significant but stable disabilities. Severe neonatal‑onset cases with marked lactic acidosis, extensive cavitating leukoencephalopathy, and early respiratory failure generally have a poor outcome. In contrast, later‑onset or milder phenotypes, including SPG74‑like presentations, may have slower progression dominated by spastic paraplegia and optic atrophy.[4][7][1][2][8][3]
Long‑term natural history data remain limited due to the rarity of the condition, but existing reports suggest that once the acute phase stabilizes, some children may show partial functional gains with intensive supportive care. Nonetheless, MMDS3 is generally regarded as a serious, often life‑limiting disorder, and early discussion of goals of care with families is recommended.[4][7][3]
Genetic counseling and reproductive options
Because IBA57 deficiency is autosomal recessive, each child of carrier parents has a 25% risk of being affected, a 50% risk of being an asymptomatic carrier, and a 25% chance of inheriting neither pathogenic variant. Identification of the familial IBA57 variants enables carrier testing for at‑risk relatives and offers options for prenatal diagnosis or preimplantation genetic testing in future pregnancies.[4][1][8][3]
Genetic counseling should address the variable expressivity of IBA57‑related disease, the current limitations in treatment, and the possibility of related phenotypes such as hereditary spastic paraplegia within the same family.[7][8][3]
Research directions
Recent research has expanded understanding of how IBA57 deficiency disrupts Fe–S cluster assembly and mitochondrial metabolism, providing a framework for future targeted therapies. Ongoing case reports and cohort studies continue to refine the clinical spectrum of MMDS3 and related IBA57‑associated phenotypes, including milder spastic paraplegia presentations and potential metabolic biomarkers. Collaborative registries and integration with rare‑disease networks such as Orphanet, NORD, and GARD aim to improve diagnosis, natural‑history characterization, and ultimately clinical trial readiness for this ultra‑rare condition.[6][12][10][1][7][8][3][4]
References
- Multiple mitochondrial dysfunctions syndrome type 3 – Orphanet – IBA57 deficiency; MMDS3. Source: PubMed ID 23462291. Prevalence: <1 / 1 000 000. Inheritance: Autoso…
- Multiple Mitochondrial Dysfunctions Syndrome 3 (MMDS3) – Multiple mitochondrial dysfunctions syndrome 3 · IBA57. 16, Invitae Organic Acidemias Panel · Multip…
- Multiple Mitochondrial Dysfunction Syndrome Type 3 – PMC – NIH – Biallelic pathogenic variants in the IBA57 gene have been shown to cause a spectrum of diseases, inc…
- multiple mitochondrial dysfunctions syndrome 3 – National Organization for Rare Disorders – Any fatal multiple mitochondrial dysfunctions syndrome in which the cause of the disease is a mutati…
- Multiple mitochondrial dysfunctions syndrome 3 (Concept Id – NCBI – Clinical, radiological, biochemical and molecular characterization of a new case with multiple mitoc…
- A novel IBA57 variant is associated with mitochondrial iron … – by PJJ Mandigers · 2023 · Cited by 9 — Pathogenic variants in human IBA57 cause multiple mitochondri…
- Multiple Mitochondrial Dysfunction Syndrome Caused … – PMC – Pathogenic variants of IBA57 (OMIM ID: 615330) are usually associated with multiple mitochondrial dy…
- Hereditary Disorders and Human Mutations of Iron-Sulfur … – Any deficiency in IBA57 can cause an autosomal recessive spastic paraplegia-74 or multiple mitochond…
- iron-sulfur cluster assembly factor IBA57 – Genes – The material is in no way intended to replace professional medical care by a qualified specialist an…
- IBA57 mutations abrogate iron-sulfur cluster assembly … – by A Ishiyama · 2017 · Cited by 38 — These previous reports suggest that IBA57 deficiency affects th…
- DISEASES – IBA57 – JensenLab – Mutations in human lipoyltransferase gene LIPT1 cause a Leigh disease with secondary deficiency for …
- Lysine and tryptophan metabolites as potential biomarkers – by P Wongkittichote · 2023 · Cited by 7 — Pathogenic variants in IBA57 have been associated with mul…
- Multiple Mitochondrial Dysfunction Syndrome Type 3 – PubMed – Multiple mitochondrial dysfunction syndrome type 3 (MMDS3) is a rare mitochondrial … IBA57. Here, …
- NM_001010867.4(IBA57):c.436C>T (p.Arg146Trp) AND … – NM_001010867.4(IBA57):c.436C>T (p.Arg146Trp) AND Multiple mitochondrial dysfunctions syndrome 3 ; Ge…
